Compare Nuvalent Inc (NUVL) vs Invesco S&P 500 Low Volatility ETF (SPLV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuvalent Inc vs Invesco S&P 500 Low Volatility ETF — how do they compare? Nuvalent Inc trades at $123.96 (market cap $9.81B), while Invesco S&P 500 Low Volatility ETF trades at $75.69. The key difference: Nuvalent Inc is trading nearer its 52-week high, Invesco S&P 500 Low Volatility ETF nearer its low. Which is the better fit depends on your goals.
| NUVL | SPLV | |
|---|---|---|
Market Cap | $9.81B | — |
Sector | Technology | — |
52-Week High | $123.96 | $77.45 |
52-Week Low | $72.16 | $70.30 |
Enterprise Value | $8.52B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nuvalent (NUVL) trades at $123.96, showing no change recently, with technical indicators presenting a mixed signal—moving averages are bullish while oscillators are bearish. The company reported a net loss of $425.38 million for 2025, with negative profitability metrics like ROE of -41.19%. Recent news highlights GSK's proposed acquisition of Nuvalent for $124 per share, totaling $10.6 billion, which is under investigation by multiple law firms for fairness concerns.
The investment outlook is heavily influenced by the pending acquisition, offering a near-term exit at $124 per share. However, risks include ongoing financial losses, negative cash flow from operations, and legal scrutiny over the deal's adequacy. Analyst sentiment is mixed with 42% buy ratings, but the acquisition provides a clear valuation anchor amid fundamental challenges.
SPLV trades at $76.09, down 0.63% on the day, with a bullish technical signal driven by moving averages. The ETF focuses on low-volatility S&P 500 stocks, offering stability amid market tensions. Recent news highlights its appeal as a defensive play during geopolitical and inflation concerns. Dividend payments of $0.14 per share are scheduled for mid-2026.
The outlook for SPLV is positive as a defensive equity holding, with low volatility strategies gaining traction in uncertain markets. Key risks include reliance on market volatility for relevance and potential underperformance in strong bull markets. Analyst sentiment is neutral to positive given current macroeconomic conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nuvalent Inc
Nuvalent, Inc. is a clinical-stage oncology company focused on creating precisely targeted therapies for patients with cancers driven by specific gene mutations. The company leverages a deep understanding of structural biology and medicinal chemistry to design novel small-molecule kinase inhibitors to overcome resistance mechanisms in advanced solid tumors. Nuvalent is committed to developing its pipeline of candidates to address high unmet needs in the treatment of various cancers.
Read more on NUVL →About Invesco S&P 500 Low Volatility ETF
The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. Strictly in accordance with its guidelines and mandated procedures, S&P Dow Jones Indices LLC (the "index Provider") compiles, maintains and calculates the underlying index, which is designed to measure the performance of the 100 least volatile constituents of the S&P 500 ® Index over the past 12 months as determined by the index Provider.
Read more on SPLV →
